Y. Liu, S. Sharma, and K. Watabe, “Roles of lncRNA in breast cancer,” Front. Biosci. (Schol. Ed)., vol. 7, no. 1, p. 94, Jun. 2015, Accessed: Aug. 03, 2021. [Online]. Available: /pmc/articles/PMC5651513/.
 Q. Lyu, L. Jin, X. Yang, and F. Zhang, “LncRNA MINCR activates Wnt/β-catenin signals to promote cell proliferation and migration in oral squamous cell carcinoma,” Pathol. - Res. Pract., vol. 215, no. 5, pp. 924–930, May 2019, doi: 10.1016/J.PRP.2019.01.041.
 A. Z, L. GD, I. E, H. HV, and M. M, “Breast cancer in young women: an overview,” Updates Surg., vol. 69, no. 3, pp. 313–317, Sep. 2017, doi: 10.1007/S13304-017-0424-1.
 L. S and L. M, “A review of clinical aspects of breast cancer,” Int. Rev. Psychiatry, vol. 26, no. 1, pp. 4–15, 2014, doi: 10.3109/09540261.2013.852971.
 N. Hauptman and D. Glavač, “Long Non-Coding RNA in Cancer,” Int. J. Mol. Sci., vol. 14, no. 3, p. 4655, Mar. 2013, doi: 10.3390/IJMS14034655.
 A. S. Calle, Y. Kawamura, Y. Yamamoto, F. Takeshita, and T. Ochiya, “Emerging roles of long non-coding RNA in cancer,” Cancer Sci., vol. 109, no. 7, pp. 2093–2100, Jul. 2018, doi: 10.1111/CAS.13642.
 Y. Zhu et al., “Construction and analysis of dysregulated lncRNA-associated ceRNA network in colorectal cancer,” J. Cell. Biochem., vol. 120, no. 6, pp. 9250–9263, Jun. 2019, doi: 10.1002/JCB.28201.
 S. S, D. R. BC, S. A, O. Y, J. Y, and L. JT, “Jpx RNA activates Xist by evicting CTCF,” Cell, vol. 153, no. 7, p. 1537, Jun. 2013, doi: 10.1016/J.CELL.2013.05.028.
 J. M et al., “Long non-coding RNA JPX correlates with poor prognosis and tumor progression in non-small-cell lung cancer by interacting with miR-145-5p and CCND2,” Carcinogenesis, vol. 41, no. 5, pp. 634–645, May 2020, doi: 10.1093/CARCIN/BGZ125.
 Z. Zahraei, A. Sarlak, and M. E. Akbari, “Investigation of c-Myc gene amplification in breast cancer patients and its correlation with other prognostic factors,” 2018.
 M. W et al., “Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma,” Clin. Res. Hepatol. Gastroenterol., vol. 41, no. 2, pp. 163–170, Mar. 2017, doi: 10.1016/J.CLINRE.2016.09.002.
 Z. Q, C. Y, and C. Z, “LncRNA MINCR regulates irradiation resistance in nasopharyngeal carcinoma cells via the microRNA-223/ZEB1 axis,” Cell Cycle, vol. 19, no. 1, pp. 53–66, Jan. 2020, doi: 10.1080/15384101.2019.1692176.
 J. Cao, D. Zhang, L. Zeng, and F. Liu, “Long noncoding RNA MINCR regulates cellular proliferation, migration, and invasion in hepatocellular carcinoma,” Biomed. Pharmacother., vol. 102, pp. 102–106, Jun. 2018, doi: 10.1016/J.BIOPHA.2018.03.041.
 W. J, D. M, Z. H, C. Y, and Z. W, “Up-regulation of long noncoding RNA MINCR promotes non-small cell of lung cancer growth by negatively regulating miR-126/SLC7A5 axis,” Biochem. Biophys. Res. Commun., vol. 508, no. 3, pp. 780–784, Jan. 2019, doi: 10.1016/J.BBRC.2018.11.162.
 T. Fukunaga, J. Iwakiri, Y. Ono, and M. Hamada, “LncRRIsearch: A Web Server for lncRNA-RNA Interaction Prediction Integrated With Tissue-Specific Expression and Subcellular Localization Data,” Front. Genet., vol. 0, no. MAY, p. 462, 2019, doi: 10.3389/FGENE.2019.00462.
 D. G et al., “MINCR is a MYC-induced lncRNA able to modulate MYC’s transcriptional network in Burkitt lymphoma cells,” Proc. Natl. Acad. Sci. U. S. A., vol. 112, no. 38, pp. E5261–E5270, Sep. 2015, doi: 10.1073/PNAS.1505753112.
 T. YY et al., “PVT1 dependence in cancer with MYC copy-number increase,” Nature, vol. 512, no. 7512, pp. 82–86, 2014, doi: 10.1038/NATURE13311.
 G. R, X. H, S. Y, J. C, and G. Q, “An efficient or methodical review of immunotherapy against breast cancer,” J. Biochem. Mol. Toxicol., vol. 33, no. 8, Aug. 2019, doi: 10.1002/JBT.22339.
 J. Xu, Y. Chen, and O. I. Olopade, “MYC and Breast Cancer,” Genes Cancer, vol. 1, no. 6, p. 629, Jun. 2010, doi: 10.1177/1947601910378691.
 Y. Fallah, J. Brundage, P. Allegakoen, and A. N. Shajahan-Haq, “MYC-Driven Pathways in Breast Cancer Subtypes,” Biomolecules, vol. 7, no. 3, Jul. 2017, doi: 10.3390/BIOM7030053.
 C. C et al., “Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis,” Carcinogenesis, vol. 34, no. 10, pp. 2300–2308, Oct. 2013, doi: 10.1093/CARCIN/BGT208.
 M. E. Ritchie et al., “limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Res., vol. 43, no. 7, pp. e47–e47, Apr. 2015, doi: 10.1093/NAR/GKV007.
 S. Davis and P. S. Meltzer, “GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor,” Bioinformatics, vol. 23, no. 14, pp. 1846–1847, Jul. 2007, doi: 10.1093/BIOINFORMATICS/BTM254.
 M. Kanehisa and S. Goto, “KEGG: Kyoto Encyclopedia of Genes and Genomes,” Nucleic Acids Res., vol. 28, no. 1, pp. 27–30, Jan. 2000, doi: 10.1093/NAR/28.1.27.
 M. Kanehisa, “Toward understanding the origin and evolution of cellular organisms,” Protein Sci., vol. 28, no. 11, pp. 1947–1951, Nov. 2019, doi: 10.1002/PRO.3715.
 M. Kanehisa, M. Furumichi, Y. Sato, M. Ishiguro-Watanabe, and M. Tanabe, “KEGG: integrating viruses and cellular organisms,” Nucleic Acids Res., vol. 49, no. D1, pp. D545–D551, Jan. 2021, doi: 10.1093/NAR/GKAA970.
 F. A et al., “Reactome graph database: Efficient access to complex pathway data,” PLoS Comput. Biol., vol. 14, no. 1, Jan. 2018, doi: 10.1371/JOURNAL.PCBI.1005968.
 J. B et al., “The reactome pathway knowledgebase,” Nucleic Acids Res., vol. 48, no. D1, pp. D498–D503, Jan. 2020, doi: 10.1093/NAR/GKZ1031.
 D. H, S. C, P. P, and G. N, “miRWalk--database: prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes,” J. Biomed. Inform., vol. 44, no. 5, pp. 839–847, Oct. 2011, doi: 10.1016/J.JBI.2011.05.002.
 D. H and G. N, “miRWalk2.0: a comprehensive atlas of microRNA-target interactions,” Nat. Methods, vol. 12, no. 8, p. 697, Jul. 2015, doi: 10.1038/NMETH.3485.
 D. Karagkouni et al., “DIANA-LncBase v3: indexing experimentally supported miRNA targets on non-coding transcripts,” Nucleic Acids Res., vol. 48, no. D1, pp. D101–D110, Jan. 2020, doi: 10.1093/NAR/GKZ1036.
 P. WX, K. P, and M. YY, “LncRNA-mediated regulation of cell signaling in cancer,” Oncogene, vol. 36, no. 41, pp. 5661–5667, Oct. 2017, doi: 10.1038/ONC.2017.184.
 B. A, S. M, and M. SS, “Long Noncoding RNA and Cancer: A New Paradigm,” Cancer Res., vol. 77, no. 15, pp. 3965–3981, Aug. 2017, doi: 10.1158/0008-5472.CAN-16-2634.
 M. Mohammadzadeh, M. Hashemi, M. Azadeh, and K. Ghaedi, “Co-expression of HOTAIR long noncoding RNA and Tbx3 transcription factor in breast cancer tissues,” Gene Reports, vol. 20, p. 100796, Sep. 2020, doi: 10.1016/J.GENREP.2020.100796.
 S. L, P. L, T. Y, K. L, and P. PP, “A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?,” Cell, vol. 146, no. 3, pp. 353–358, Aug. 2011, doi: 10.1016/J.CELL.2011.07.014.
 W. SH et al., “Long non-coding RNA MINCR promotes gallbladder cancer progression through stimulating EZH2 expression,” Cancer Lett., vol. 380, no. 1, pp. 122–133, Sep. 2016, doi: 10.1016/J.CANLET.2016.06.019.
 Y. Y et al., “Long non-coding RNA MINCR aggravates colon cancer via regulating miR-708-5p-mediated Wnt/β-catenin pathway,” Biomed. Pharmacother., vol. 129, Sep. 2020, doi: 10.1016/J.BIOPHA.2020.110292.
 C. S et al., “Roles of MYC-targeting long non-coding RNA MINCR in cell cycle regulation and apoptosis in non-small cell lung Cancer,” Respir. Res., vol. 20, no. 1, Sep. 2019, doi: 10.1186/S12931-019-1174-Z.
 C.-S. M, M. L, and E. RN, “An overview of MYC and its interactome,” Cold Spring Harb. Perspect. Med., vol. 4, no. 1, 2014, doi: 10.1101/CSHPERSPECT.A014357.
 S. ZE, W. ZE, A. BJ, H. AL, and D. CV, “MYC, Metabolism, and Cancer,” Cancer Discov., vol. 5, no. 10, pp. 1024–1039, Oct. 2015, doi: 10.1158/2159-8290.CD-15-0507.
 E. M, U. T, Y. H, and S. K, “Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer,” Int. J. Mol. Sci., vol. 20, no. 9, May 2019, doi: 10.3390/IJMS20092340.
 S. Mashhadizadeh et al., “PGR and TUG1 overexpression: A putative diagnostic biomarker in breast cancer patients,” Gene Reports, vol. 21, Dec. 2020, doi: 10.1016/J.GENREP.2020.100791.
 Y. Chen and O. I. Olopade, “MYC in breast tumor progression,” Expert Rev. Anticancer Ther., vol. 8, no. 10, p. 1689, 2008, doi: 10.1586/14737188.8.131.529.
 J. R, N. X, H. Y, and W. X, “β-Catenin is important for cancer stem cell generation and tumorigenic activity in nasopharyngeal carcinoma,” Acta Biochim. Biophys. Sin. (Shanghai)., vol. 48, no. 3, pp. 229–237, Sep. 2016, doi: 10.1093/ABBS/GMV134.
 P. SG, B. N, A. M, A. F, K. AP, and D. A, “Wnt signaling in triple-negative breast cancer,” Oncogenesis, vol. 6, no. 4, Apr. 2017, doi: 10.1038/ONCSIS.2017.14.
 C. VH and C. MD, “Turning the tables: Myc activates Wnt in breast cancer,” Cell Cycle, vol. 6, no. 21, pp. 2625–2627, Nov. 2007, doi: 10.4161/CC.6.21.4880.
 Y.-S. Jung and J.-I. Park, “Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex,” Exp. Mol. Med. 2020 522, vol. 52, no. 2, pp. 183–191, Feb. 2020, doi: 10.1038/s12276-020-0380-6.
 P. J et al., “lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling,” Mol. Cancer, vol. 19, no. 1, Jan. 2020, doi: 10.1186/S12943-020-1133-9.
 L. J, F. L, T. C, T. YL, T. Y, and H. FQ, “Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway,” Eur. Rev. Med. Pharmacol. Sci., vol. 22, no. 23, pp. 8135–8144, 2018, doi: 10.26355/EURREV_201812_16505.
 E. Ezzati, S. Mosadeshi, A. Akbarinia, S. Horriat, M. Rezaei, and M. Azadeh, “LINC00520 promotes breast cancer development by low expression as a tumor suppressor and prognostic biomarker by regulating the ESR2 expression level: integrated systems biology bioinformatics and experimental analyses,” Aug. 2022, doi: 10.21203/RS.3.RS-1944462/V1.
 N. Tavousi et al., “ADAMTS5 modulates breast cancer development as a diagnostic biomarker and potential tumor suppressor, regulating by BAIAP2-AS1, VTI1B, CRNDE, and hsa-miR-135b-3p: integrated systems biology and experimental approach,” Jul. 2022, doi: 10.21203/RS.3.RS-1861409/V1.